🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are increasing globally, with estimates suggesting in excess of 82 million instances per year. Notably increased rates are observed in Africa and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Secure Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This approval signifies a significant shift in the management of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Results and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which involves two antibiotics. The study included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the rights to register and commercialise the drug in numerous developing nations.

Medical professionals treating patients have shared positive views. The availability of a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is viewed as vital to alleviate the strain of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea globally.